The DIAN-TU acknowledges the many individuals who have contributed to the DIAN-TU Trials including funding partners, leadership team, core leaders, project arm leaders, study sites and institutional study partners.
Through public/private support and partnership, the DIAN-TU has launched trials to provide advancement of treatments, scientific understanding, and improvements in the approach to Alzheimer’s disease drug developments.
- Alzheimer’s Association
- DIAN-TU Pharma Consortium: AbbVie, Biogen, Bristol Myers Squibb, Eisai, Ionis, Janssen, Lilly, Prothena, Roche/Genentech (Former Members: Amgen, AstraZeneca, Elan, Forum, Mithridion, Novartis Pharm AG, Pfizer, Sanofi-Aventis, United NeuroScience)
- National Institute on Aging of the National Institutes of Health: U01 AG042791 (completed), R01 AG046179 (completed), R01/R56 AG053267, R01 AG068319, U01 AG059798, R13 AG055232
- Accelerating Medicines Partnership (AMP)
- DIAN-TU Trial Industry Partners:
- Eli Lilly and Company (Solanezumab)
- F. Hoffmann-La Roche (Gantenerumab)
- Janssen (Atabecestat)
- Eisai (E2814)
- Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company
- GHR Foundation
- Anonymous Foundation
- CogState
- Signant Health
- Cerveau Technologies
DIAN-TU Support
Randall Bateman, MD
Principal Investigator & Program Director
- Phone: 314-286-1674
- Email: batemanr@wustl.edu
Study Team | Funding | History
Study details (DIAN-TU-001) on clinicaltrials.gov
For Investigators
Visit Investigator Resources for information on accessing resources and participation policies.